Q2
CNSP — Q2 2026 Financial Report Analysis
CNS Pharmaceuticals raised $22.5M at $2.30 a share, lifting cash to $20.0M and removing its going-concern warning, but the deal gave new investors ~92% of the share count; Q2 net loss widened 9% to $2.6M as the company hunts for a new drug after Berubicin's trial miss.